

IMAGES IN CLINICAL PRACTICE

NEONATAL LUPUS ERYTHEMATOSUS - A CAUSE TO REMEMBER IN NEWBORN DERMATOSIS

Mariana Silva Duarte¹, Filomena Pinto², Rodrigo Carvalho³, Marta Conde⁴.

¹Medical Paediatric Unit, Área de Pediatria, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central – EPE, Lisbon, Portugal,

²Neonatal Intensive Care Unit, Área de Pediatria, Maternidade Alfredo da Costa, Centro Hospitalar de Lisboa Central – EPE, Lisbon, Portugal,

³Dermatology Department, Hospital dos Capuchos, Centro Hospitalar de Lisboa Central – EPE, Lisbon, Portugal,

⁴Pediatric Rheumatology Unit, Área de Pediatria, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central – EPE, Lisbon, Portugal.

KEYWORDS

neonatal lupus, diagnosis, cutaneous manifestations.

ARTICLE HISTORY

Received 7 December 2022

Accepted 26 December 2022

We describe a case of a female newborn, from mother with systemic lupus erythematosus (SLE), with onset of skin lesions since day seven of life. Examination revealed six annular, erythematous, scaly patches on the face, trunk and lower extremities (Figures 1 and 2). Laboratory tests showed hemoglobin 9.6 g/dL, leukocytes $8.77 \times 10^9/L$, platelets $239 \times 10^9/L$, ANA $>1/640$ and positive extractable nuclear antigens (ENAs) (anti-Ro/SSA, anti-La/SSB and RNP/Sm). Cardiologic evaluation didn't reveal anomalies. Skin biopsy showed apoptotic keratocytes with hydropic degeneration of the basal epidermis and perivascular lymphocytic infiltrate of the dermis compatible with neonatal lupus (NLE). Low potency topical corticosteroids (LPTC) were started.

Because of skin worsening (Figure 3), liver enzymes elevation (AST 225 U/L, ALT 87 U/L), and thrombocytopenia ($115 \times 10^9/L$), low-dose systemic corticosteroids (SC) were started. Progressive reduction of SC until discontinuance was possible with normalization of the laboratory results and skin remission

Figure 1. Scaly patches on the face.



Figure 2. Scaly patches on the trunk and lower extremities.



Figure 3. Skin worsening.



What is the diagnosis?

NLE is a rare autoimmune disease resulting from the passive transfer of maternal autoantibodies (MAA) (anti-Ro/SSA, anti-La/SSB and/or Anti-U1RNP) to fetus. Congenital heart block may be detected in utero (2nd trimester) and is the classic cardiac manifestation, being determinant for prognosis because it is usually permanent and may require pacemaker placement. Half of the patients present cutaneous manifestations that typically resolve until the first year of life (disappearance of MAA) and less frequently may

Address for Correspondance: Mariana Duarte, Rua Jacinta Marto, 1169-045 Lisboa, Portugal.

Email: marianaduarte@campus.ul.pt

©2025 Pediatric Oncall

present hepatobiliary and hematological involvement.^{1,2} The diagnosis of NLE is based on clinical features and autoantibodies identification, but sometimes skin biopsy might be needed. Photoprotection and LPTC for short periods of time are the treatment of choice for cutaneous involvement, but SC can be used in patients with hepatobiliary and hematological manifestations.^{1,3,4} Specially in cases without a previous diagnosis of the mother (40-60%), NLE diagnosis requires a high level of suspicion because cutaneous manifestations may mimic other common dermatosis. Even in mothers with previous SLE diagnosis, only 1-2% will have children with NLE (coexistence of Ac anti-Ro and anti-La increases this risk). Cardiological and laboratory evaluation is mandatory during pregnancy and after birth, allowing optimization of clinical care.^{2,4}

Compliance with Ethical Standards**Funding** None**Conflict of Interest** None**References:**

1. Teixeira AR, Rodrigues M, Guimarães H, Mura C, Brito I. Neonatal lupus - case series of a tertiary hospital. *Acta Reumatol Port* 2012; 42:318-23
2. Izmirly PM, Halushka MK, Rosenberg AZ, Whekton S, Rais-Bahrami K, Nath DS, et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. *Autoimmun Rev* 2017; 16: 980-3
3. Wisuthsarewong W, Soongswang J, Chantorn R. Neonatal Lupus erythematosus: clinical character, investigation and outcome. *Pediatr Dermatol* 2011; 28 (2): 115-21
4. Hon KL, Leung AK. Neonatal lupus erythematosus. *Autoimmune Dis.* 2012; 2012:1-6